Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC.

JTO Clin Res Rep · 2025 · PMC12509971 · PMID 41080090

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

4 Overall survival (OS) analyses at SA1 revealed a numerical trend favoring D+CT versus P+CT (median 19.4 months [95% CI: 14.5–not reached] versus 15.9 months [95% CI: 11.6–19.3]; HR: 0.75 [95% CI: 0.53–1.05]; 55% maturity), 5 which was maintained at SA2 (DCO April 30, 2024; 20.2 mo [95% CI: 14.5–27.3] versus 15.9 mo [95% CI: 11.6–19.3]; HR: 0.74 [95% CI: 0.54–1.0

also in 624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.